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A second aﬀ ordable oral cholera vaccine: implications for the 
global vaccine stockpile 
On Dec 23, 2015, WHO prequaliﬁ ed a second aﬀ ordable 
oral cholera vaccine (OCV), Euvichol (Eubiologics, South 
Korea), which is expected to double current global OCV 
production and has the potential to further increase 
production capacity.1 The increased production will have 
implications for vaccine availability and reduced costs 
per dose, and will ultimately represent an added value 
for global cholera prevention and control. 
Vaccine prequaliﬁ cation is a WHO-led activity intended 
to ensure that vaccines purchased by UN procurement 
agencies will be acceptable under conditions of use in 
national immunisation programmes in low-income and 
middle-income countries (LMICs).2 Prequaliﬁ cation also 
indicates that a vaccine meets WHO recommendations 
for quality, safety, and eﬃ  cacy—enabling wider 
implementation of the vaccine in resource-
limited contexts.
Cholera is endemic in more than 50 countries, with 
an estimated at-risk population of 1·5 billion, plus an 
annual estimated morbidity of more than 2 million cases 
and nearly 100 000 deaths.3 However, public attention is 
only garnered when outbreaks strike disaster-ravaged 
areas. Successful cholera control depends on a long-term 
commitment to improve water quality and sanitation 
systems, but an eﬀ ective vaccine serves as an important 
component in a comprehensive prevention package.
In 2001, WHO prequaliﬁ ed the OCV Dukoral 
(SBLVaccin, Sweden) for purchase by UN agencies. 
Through a successful technology transfer agreement, 
a modiﬁ ed bivalent formulation, Shanchol (Shantha 
Biotechnics, India), was developed and manufactured 
and was prequaliﬁ ed in 2011. Both Shanchol and 
the newly prequaliﬁ ed Korean vaccine (Euvichol) are 
reformulated versions of Dukoral. Because these newer 
versions do not contain the cholera toxin, they do not 
require co-administration with an oral buﬀ er, making 
these versions both easier to deliver in challenging ﬁ eld 
conditions and substantially less costly for the standard 
two-dose regimen (US$3·7 for Shanchol and Euvichol vs 
>$10·5 for Dukoral).4
In July, 2013, a global OCV stockpile was created. A 
stockpile is a mechanism to encourage change in vaccine 
use for underserved populations: a change from low 
demand, low production, high unit costs, and inequitable 
distribution, to an increased demand and production, 
lower unit costs, and greater equity of distribution. 
The Gavi Alliance approved funding of US$115 million 
from 2014–18 for a global stockpile delivery strategy for 
use in epidemic and endemic settings. Since inception, 
21 shipments of OCV have been approved to be used 
in large preventive or reactive vaccination campaigns 
(about 4 million doses) in 11 countries. Because of limited 
supply, OCV is released from this stockpile after review 
and recommendation of country applications by the 
International Coordinating Group, composed of UNICEF, 
Médecins Sans Frontières, The International Federation 
of Red Cross, and WHO. The vaccine has been used 
successfully in various contexts—humanitarian crises (eg, 
South Sudan and Ethiopia), disease outbreaks (eg, Guinea, 
Malawi, Tanzania, and Iraq), and endemic hotspots (eg, 
Bangladesh, Democratic Republic of Congo, and Haiti).5 
A major development during 2015 was that OCV 
demand exceeded supply (ﬁ gure). The main reasons 
for this increase in demand are the observed feasibility 
of mass OCV campaigns and their ability to confer 
Figure: Cholera vaccine demand, use, and production during 1997–2015
Since 2013, the International Coordinating Group has served as the decision body as to whether OCV is deployed 
through the global stockpile. GTFCC=Global Task Force on Cholera Control. OCV=oral cholera vaccine.
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protection to underserved populations in complex 
situations.6–8 The increased availability and use of OCV has 
a multifaceted added value. OCV and established cholera 
response measures (eg, water, sanitation, and hygiene 
[WASH] measures; treatment regimens; surveillance; 
and social mobilisation) have often been viewed in the 
past as competitive, if not mutually exclusive. With 
greater awareness and use of OCV, these measures and 
vaccines are now being considered as complimentary 
and have proven to be synergistic on many occasions.9 
In this sense, the stockpile becomes an operational 
data generator. In other words, with emphasis on 
vaccine availability accompanying the use of OCV, many 
donors and partners have worked together within the 
framework of the Global Task Force on Cholera Control to 
show the public health potential of a coordinated eﬀ ort 
against cholera. The growing body of evidence of vaccine 
eﬀ ectiveness and costing data is contributing to inform 
large investments in integrated control and prevention 
strategies. Over recent years, countries have become 
more prepared to report cholera, which is an important 
and positive change from the past, in which political and 
economic imperatives prevailed. 
For too long the response to cholera epidemics has 
been purely reactive. OCV might be a key to the door 
for prevention and control of a disease that is often 
overlooked until epidemics are too advanced for a 
vaccine to be eﬀ ective. WHO prequaliﬁ cation of a 
second aﬀ ordable OCV represents an important step 
forward in achieving the stockpile goals of increased 
availability and distribution to aﬀ ected populations. 
Although the increased access and awareness of OCV is 
not the absolute solution for cholera, it certainly serves 
as a substantial step towards achieving a complete 
prevention and control strategy.
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